Dr Andrew Mark Thompson

Selected publications and creative works (Research Outputs)

  • Thompson, A. M., O'Connor PD, Marshall, A. J., Blaser, A., Yardley, V., Maes, L., ... Chatelain, E. (2018). Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of medicinal chemistry, 61 (6), 2329-2352. 10.1021/acs.jmedchem.7b01581
    Other University of Auckland co-authors: Adrian Blaser, Bill Denny
  • Thompson, A. M., Marshall, A. J., Maes, L., Yarlett, N., Bacchi, C. J., Gaukel, E., ... Chatelain, E. (2018). Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic & medicinal chemistry letters, 28 (2), 207-213. 10.1016/j.bmcl.2017.10.067
    Other University of Auckland co-authors: Bill Denny
  • Thompson, A. M., Bonnet, M., Lee, H. H., Franzblau, S. G., Wan, B., Wong, G. S., ... Denny, W. A. (2017). Antitubercular nitroimidazoles revisited: Synthesis and activity of the authentic 3-Nitro isomer of pretomanid. ACS Medicinal Chemistry Letters, 8 (12), 1275-1280. 10.1021/acsmedchemlett.7b00356
    Other University of Auckland co-authors: Ho Lee, Bill Denny
  • Thompson, A. M., Blaser, A., Palmer, B. D., Anderson, R. F., Shinde, S. S., Launay, D., ... Wan, B. (2017). 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 27 (11), 2583-2589. 10.1016/j.bmcl.2017.03.069
    URL: http://hdl.handle.net/2292/34389
    Other University of Auckland co-authors: Brian Palmer, Adrian Blaser, Bob Anderson, Bill Denny
  • Thompson, A. M., O'Connor PD, Marshall, A. J., Yardley, V., Maes, L., Gupta, S., ... Franzblau, S. G. (2017). 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis. Journal of Medicinal Chemistry, 60 (10), 4212-4233. 10.1021/acs.jmedchem.7b00034
    URL: http://hdl.handle.net/2292/35110
    Other University of Auckland co-authors: Bill Denny
  • Satam, V. S., Pedada, S. R., Kamaraj, P., Antao, N., Singh, A., Hindupur, R. M., ... Martin, D. (2017). Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis. Organic Process Research and Development, 21 (1), 52-59. 10.1021/acs.oprd.6b00331
    URL: http://hdl.handle.net/2292/33077
  • Smaill, J. B., Gonzales, A. J., Spicer, J. A., Lee, H., Reed, J. E., Sexton, K., ... Blaser, A. (2016). Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4- d ]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of Medicinal Chemistry, 59 (17), 8103-8124. 10.1021/acs.jmedchem.6b00883
    URL: http://hdl.handle.net/2292/32487
    Other University of Auckland co-authors: Jeffrey Smaill, Bill Denny, Julie Spicer, Brian Palmer, Adrian Blaser
  • Thompson, A. M., O'Connor PD, Blaser, A., Yardley, V., Maes, L., Gupta, S., ... Wan, B. (2016). Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 59 (6), 2530-2550. 10.1021/acs.jmedchem.5b01699
    URL: http://hdl.handle.net/2292/30023
    Other University of Auckland co-authors: Adrian Blaser, Bill Denny

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 117
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand